Navigation Links
Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
Date:2/29/2008

ther than temporary."

The accounting treatment and final results for 2007 may change based upon final third party valuations regarding these securities. If uncertainties in the credit market continue, these markets deteriorate further or the company experiences any ratings downgrades on its investments in ARS, the company may incur additional impairments to its investment in ARS. The Company believes that based on its current cash, cash equivalents, short and long term bank deposits and marketable securities balances at December 31, 2007 and its expected operating cash flows, the current lack of liquidity of these securities will not have a material impact on the Company's ability to fund its operations, unless this current lack of liquidity persists after the third quarter of 2009.

Details reconciling non-GAAP amounts with GAAP amounts including specified items are provided in the table attached.

Recent Highlights

Rosetta Genomics reports the following scientific and corporate highlights:

Diagnostic Programs

- Squamous vs. Non Squamous non-small cell lung cancer (NSCLC) - Bevacizumab (Avastin(R)[1]) in combination with carboplatin and paclitaxel, is indicated for first line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous, NSCLC cancer, and the package labeling warns that the incidence of severe or fatal hemoptysis was 31% in patients with squamous histology and 2.3% in patients with NSCLC excluding predominant squamous histology. However, no objective, standardized test for differentiating squamous from non-squamous NSCLC is currently available commercially. A novel test to differentiate squamous vs. non-squamous NSCLC based on a single microRNA biomarker applying the Rosetta Genomics technology is being validated and is expected to be filed with the New York Department of Health during H1 2008.

- Mesothelioma vs. Adenocarcinoma - Differentiating between mesothelioma vs
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Rosetta Genomics Establishes Medical Advisory Board
2. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
3. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
4. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
5. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
6. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
7. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
8. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
9. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
10. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
11. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... HILL, N.C. , Dec. 22, 2014 /PRNewswire/ ... today announced that it has signed a letter ... company that has developed and patented a nanotechnology-based ... medical diagnostics products that enable rapid on-site collection ... alcohol use/abuse and health issues in an immediate, ...
(Date:12/22/2014)... MISSION VIEJO, Calif. , Dec. 22, 2014 /PRNewswire/ ... announce that CoPatient, an online medical bill review and ... newest offering in the FREE WellCard Savings discount health ... a medical bill that was more than they expected ... help members reduce health care costs, WellCard Savings is ...
(Date:12/22/2014)... Illinois (PRWEB) December 22, 2014 ITRA ... tenants and occupiers of commercial real estate, has further ... new offices in Perth and Brisbane, Western Australia, reports ... of directors. , ITRA Global / ACORPP (Australian ... totally independent consultancy company providing property services to a ...
(Date:12/19/2014)... OR and Hershey, PA (PRWEB) December 19, 2014 ... Pink: BJCT), a leading developer and manufacturer of ... entered into an agreement with Immunomic Therapeutics, Inc. ... Biojector®-2000 needle-free injection device with its LAMP™ vaccine ... an option for an exclusive Worldwide license to ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... the challenge has been to generate a similarly large ... odors in the real world. A further requirement is ... precision and reproducibility. , In a new study published ... White, Mary AtKisson, John Kauer and colleagues demonstrate a ...
... - Lorus Therapeutics Inc. (TSX:,LOR; AMEX: LRP), a ... pharmaceutical products and technologies for the management,of cancer, ... team,with the appointment of Mr. Peter Korth to ... Korth has previously held senior financial and business ...
... A free white paper for clinical,laboratory managers titled: ... Biotech, Inc. at, http://www.aicompanies.com/anoxomat ., As hospital ... with the ongoing challenge of quickly determining the ... As a result, clinical laboratories,face growing pressure to ...
Cached Biology Technology:Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer 2Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer 3Free White Paper Available for Clinical Laboratory Managers: 'Effectively Isolating Anaerobic Bacteria' 2
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... entertainer and security consultant, Apollo Robbins for ... smart wallet.  Apollo Robbins ... 7 th , 2015, demonstrating some of his famous ...
(Date:12/22/2014)... -- The 2014 Holiday Season may be the brightest ... Intelligence reports that the long anticipated floodgates for ... that intensifying demand for smart phones, tablets, and ... a global market of 2.5 billion users with ... According to Maxine Most , ...
(Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ... Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter security ... 3.6% from 2014 to 2019. Although the U.S. market ... Canada is expected to grow at a ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3
... continents have engineered an efficient and environmentally friendly catalyst ... used extensively in modern industry to manufacture fertilizer and ... abundant element, it is generally not found as the ... water (H2O) or to carbon in methane (CH4), the ...
... tool may be able to improve its specificity. ... Nature Biotechnology , Massachusetts General Hospital (MGH) investigators describe ... (gRNA) component of the synthetic enzymes called CRISPR-Cas RNA-guided ... mutations at sites other than the intended target, a ...
... have discovered that breast stem cells and their ,daughters, ... are active in puberty and throughout life. The ... that they could harbour genetic defects or damage that ... timeline of breast cancer development. The finding is also ...
Cached Biology News:Engineers teach old chemical new tricks to make cleaner fuels, fertilizers 2Engineers teach old chemical new tricks to make cleaner fuels, fertilizers 3Engineers teach old chemical new tricks to make cleaner fuels, fertilizers 4Shortening guide RNA markedly improves specificity of CRISPR-Cas nucleases 2Long-lived breast stem cells could retain cancer legacy 2
... antibody raised against a partial ... Immunogen: SLC22A3 (NP_068812, 90 ... recombinant protein with GST tag. ... NM_021977 ...
Mouse monoclonal antibody raised against a partial recombinant AAAS. NCBI Entrez Gene ID = AAAS...
Mouse monoclonal antibody raised against a partial recombinant PUM2. NCBI Entrez Gene ID = PUM2...
...
Biology Products: